The episode discusses a new pancreatic cancer drug, evidence-based guidelines, and the role of AI in medicine, among other topics.
We're trying to become better listeners, SO PREPARE FOR SOME SHOUTING 🤭 Originally streamed LIVE on YouTube! (#41) We cover the new pancreatic cancer drug daraxonrasib and its rash side effect, survival benefit, and cost; what makes pancreatic cancer especially deadly; Vinay’s clinical background across hematology and oncology; how mechanistically cancer actually kills; the challenge of finding good podcast guests and why authenticity matters more than plugging a product; vaccine mandates and the difference between individual versus population-level benefit; the USPSTF’s recent upheaval and the challenge of evidence-based guidelines on contested topics like depression screening, mammograms, and prostate cancer screening; observational versus randomized evidence, with examples spanning flu vaccines, shingles vaccines and dementia, and Tylenol in pregnancy and autism; the OpenAI Navier-Stokes controversy and AI’s role in mathematics; AI in medicine and a JAMA perspective piece on AI replacing physicians; statins, coronary calcium scores, and personal decision-making around cardiovascular risk; weight stigma in medical training and the complexity of obesity; alternative medicine…
Hosts: Dr. Vinay Prasad, Zubin Damania
Organizations: USPSTF, OpenAI, JAMA
Products: daraxonrasib
Explore listener stats, chart rankings, contacts and more on the The VPZD Show podcast page.